On December 7, 2022 CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, reported that Phase 2 data for CX-2009, a conditionally activated antibody drug conjugate (ADC) targeting CD166, will be presented at the San Antonio Breast Cancer Symposium on December 8th (Press release, CytomX Therapeutics, DEC 7, 2022, View Source [SID1234624885]). The poster details the results from patients treated with monotherapy praluzatamab ravtansine for the treatment of advanced HR+/HER2- breast cancer and triple negative breast cancer (TNBC).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We thank our investigators and the patients and families who contributed to our comprehensive evaluation of praluzatamab ravtansine in breast cancer. Although we elected previously in 2022 not to advance this program further without a partner, this research has benefited many patients, provided important insights into our conditionally activated ADC strategy and informed our next generation of Probody therapeutic candidates," said Sean McCarthy, D.Phil, CEO and Chairman of CytomX.
Details for the poster presentation are as follows:
Presentation Title: Results from a phase 2 study of praluzatamab ravtansine (CX-2009) in patients with advanced breast cancer (ABC)
Poster: P4-01-15
Session and Location: Poster Session 4 – Hall 1
Session Date and Time: December 8, 2022, 7:00 am – 8:15 am CT
Presenting Author: Dr. Kathy Miller, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, USA